Skip to Main Content
Home
Team
15
Careers
1
Investments
25
News
299
Home
Team
15
Careers
1
Investments
25
News
299
Back to News
9.6.2022
Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction